Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A3471086 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the analgesic efficacy and general safety of 2 dosing regimens of valdecoxib compared to placebo on the first post-operative day in patients with moderate or severe pain following bunionectomy surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Active Comparator |
| |
| Arm 2 | Active Comparator |
| |
| Arm 3 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| valdecoxib | Drug | valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose |
|
| Measure | Description | Time Frame |
|---|---|---|
| Summed Pain Intensity Difference (categorical) through 24 hours (SPID 24) | Day 1 | |
| Total Pain Relief through 24 hours (TOTPAR 24) | Day 1 | |
| Patient's Global Evaluation of Study Medication | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| time between doses of study medication | Day 1 | |
| Time-specific Pain Intensity Difference (PID) (categorical) | 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours | |
| time-specific pain relief |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | 85015 | United States | ||
| Pfizer Investigational Site |
Not provided
Not provided
Not provided
Not provided
Not provided
| valdecoxib/placebo | Drug | valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose |
|
| placebo | Drug | placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose |
|
| 2, 4, 6, 8, 10, 12, 16, and 24 hours |
| time-specific PID (VAS) | 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours |
| Summed Pain Intensity (SPID)24 (VAS) | 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours |
| time to rescue medication | 2, 4, 6, 8, 10, 12, 16, and 24 hours |
| percent of patients who took rescue medication | Day 1 |
| Patient's Satisfaction Questionnaire | Day 1 |
| Phoenix |
| Arizona |
| 85016 |
| United States |
| Pfizer Investigational Site | Phoenix | Arizona | 85020 | United States |
| Pfizer Investigational Site | Phoenix | Arizona | 85032 | United States |
| Pfizer Investigational Site | Tempe | Arizona | 85281 | United States |
| Pfizer Investigational Site | Anaheim | California | 92701 | United States |
| Pfizer Investigational Site | Chula Vista | California | 91911 | United States |
| Pfizer Investigational Site | San Diego | California | 92114 | United States |
| Pfizer Investigational Site | Santa Ana | California | 92701 | United States |
| Pfizer Investigational Site | Tustin | California | 92780 | United States |
| Pfizer Investigational Site | Lexington | Kentucky | 40504 | United States |
| Pfizer Investigational Site | Lexington | Kentucky | 40509 | United States |
| Pfizer Investigational Site | Lexington | Kentucky | 40515 | United States |
| Pfizer Investigational Site | Altoona | Pennsylvania | 16602 | United States |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | United States |
| Pfizer Investigational Site | Johnson City | Tennessee | 37601 | United States |
| Pfizer Investigational Site | Johnson City | Tennessee | 37604 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78229 | United States |
| Pfizer Investigational Site | San Antonio | Texas | 78240 | United States |
| Pfizer Investigational Site | Salt Lake City | Utah | 84117 | United States |
| Pfizer Investigational Site | Salt Lake City | Utah | 84123 | United States |
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D006215 | Hallux Valgus |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D005530 | Foot Deformities |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C406224 | valdecoxib |
Not provided
Not provided
Not provided